Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT07511283
Recruiting Observational

Calciphylaxis in Patients With Chronic Kidney Disease - A Study of the Danish Calciphylaxis Research Initiative (DanCaRI)

NCT07511283 · tracked via the Priya Life Science Denmark tracker
Sponsor
Odense University Hospital
Phase
Observational
Started
2026-04
Last updated
2026-04-06

Condition(s) studied

CalciphylaxisCalcific Uremic ArteriolopathyEnd Stage Renal Disease (ESRD)Chronic Kidney DiseasesNephrogenic Calciphylaxis

Study summary

Calciphylaxis is a rare yet life-threatening condition involving pronounced calcification in small blood vessels of the skin.

Knowledge about its underlying mechanisms and contributing risk factors remains limited. Chronic kidney disease is one of the strongest disease predictors. No evidence based effective therapy is currently available. Research on the topic is mainly hindered by the condition's rarity.

The study Calciphylaxis in patients with chronic kidney disease - A study of the Danish Calciphylaxis Research Initiative (DanCaRI) is set up to facilitate the systematic retrospective and prospective comparison of patients with chronic kidney disease and calciphylaxis to matched patients with chronic kidney disease who did not develop calciphylaxis thereby providing new knowledge that can support prevention, early detection, and new treatment approaches.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Cases * Age ≥18 years. * CKD. * Suspicion of calciphylaxis or newly diagnosed calciphylaxis episode. The suspicion or diagnosis of calciphylaxis is a mutual decision of the involved medical specialties (nephrologist, dermatologist, pathologist, other). * Ability to give informed consent. * Ability to participate in a clinical study as assessed by the local investigator. * Provides written informed consent. Controls * Age ≥18 years. * CKD * Ability to give informed consent. * Ability to participate in a clinical study as assessed by the local investigator. * Provides written informed consent. Healthy reference group * Age ≥18 years. * Self-assessed as healthy, confirmed by local investigators at inclusion Exclusion Criteria: Cases \- the calciphylaxis diagnosis becomes excluded Controls - Being diagnosed with calciphylaxis Healthy controls Up to 60 years of age: eGFR below 60 ml/min/1.72m2. \- Over 60 years of age: eGFR below the 95% confidence interval for eGFR adjusted for age (Danish Society of Nephrology references ranges)

Primary outcome measure(s)

  • All-cause mortality — 3 year follow up period
    Associations between disease status (case or control), clinical and laboratory variables, molecular parameters, and all-cause mortality will be evaluated.

Trial sites (1)

FacilityCityRegionStatus
Odense University Hospital Odense Denmark Recruiting

More Odense University Hospital trials in Denmark

Ultrasound Applicability in the Assessment of Patients With Fibrosing Interstitial Lung Disease Enrolling by invitation
Continuous Bloodsugar Monitoring System With a Sensor Compared to Fingerstick Bloodsugar Monitoring Recruiting
Immunotherapy in Patients With Early dMMR Rectal Cancer Recruiting
Permissive Hyperthermia in Acute Brain Injury Active, not recruiting
Vitamin D and Angiogenic Markers in Odense Child Cohort 1 Active, not recruiting

Other trials for the same condition

A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record Recruiting
Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors Recruiting
Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease Recruiting
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease Recruiting
Multiparametric MRI in Healthy Volunteers and CKD Patients Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07511283 on ClinicalTrials.gov ↗ ← All trials in Denmark